Vanda says its drug can halve vomiting risk in patients using GLP-1s

Vanda Pharmaceuticals said a drug candidate that it licensed from Eli Lilly significantly reduced vomiting and nausea rates in a mid-stage trial of overweight and obese people taking a GLP-1 agonist. Around 29% of patients ...